BRAHMS GmbH | Date: 2016-06-13
The invention relates to a method for diagnosing and/or stratifying the risk of infections or chronic diseases of the respiratory tract and lungs, particularly lower respiratory tract infections and chronic obstructive pulmonary disease. In said method, provasopressin (proAVP) or fragments or partial peptides thereof, especially copeptin or neurophysin II, is/are determined. The invention further relates to suitable biomarker combinations for in-vitro diagnosis.
B.R.A.H.M.S Gmbh | Date: 2017-01-23
The present invention relates to an in vitro method for the detection of Procalcitonin or a fragment thereof of at least 20 amino acid residues in length in a biological sample derived from a bodily fluid obtained from a subject, comprising the steps of: (i) contacting said sample with at least two antibodies or functional fragments thereof directed against different epitopes within Procalcitonin, and (ii) qualitatively or quantitatively detecting binding of said at least two antibodies to Procalcitonin or said fragment thereof, wherein binding indicates the presence or concentration of Procalcitonin or said fragment in said sample, wherein at least one antibody or functional fragment thereof is directed against an epitope comprised in the sequence spanning amino acid residues 2 to 52 of Procalcitonin. The invention also pertains to antibodies directed against an N-terminal epitope of Procalcitonin and kits comprising antibodies directed against PCT.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: ICT-26-2014 | Award Amount: 3.39M | Year: 2015
The diagnosis and management of acute Sepsis is a critical area where fast and accurate results can translate into life changing health outcomes for individuals. The overall aim of RAIS is to develop a new point-of-care label-free microarray platform and validate it for quantifying levels of specific Sepsis biomarkers. The approach uses a novel interferometric technique ultimately capable of providing very large arrays of tests. Specific objectives and activities include: (i) an optical microarray reader based on a disruptive proprietary design combining interferometric lens-free microscopy and proximity CCD or CMOS image sensing; (ii) a microarray plate, in a proper microfluidic cartridge, consisting of a transparent slide with a novel nano-structured surface geometry to increase the detection sensitivity and covered by specific receptors to capture bio-markers; (iii) their integration in a portable and battery powered label free microarray platform potentially capable of measuring more than 1 million bio-targets simultaneously. The developed technology will be capable to detect micro-ribonucleic acids (microRNAs), interleukins and other specific proteins associated to Sepsis using a few microliters of blood or serum samples, in a concentration of a few pg/ml, within 30 minutes (sample to result) and at a cost per patient of less than 50. In this way, patients will be put on the right treatment more rapidly, potentially reducing the Sepsis mortality rate of more than 70%, with estimated cost savings of more than 10 billion per year as a consequence of shorter hospital stays, reduced use of unnecessary drugs and lower associated insurance bills. The technical approach, targeted device, application and the addressed market sector are perfectly in line with the call H2020-ICT-2014-1 - Photonics KET - Biophotonics for screening of diseases: Mobile, low-cost point-of-care screening devices for reliable, fast and non- or minimally-invasive detection of diseases.
Brahms GmbH | Date: 2016-02-05
The invention relates to a method for the diagnosis and/or risk stratification of cardiac diseases and diseases of the respiratory tract and lungs. According to said method, the free fragment N-terminal proEndothelin (NT-proET-1; amino acids 18-52 of the preproET according to FIG. 1) or fragments and partial peptides thereof is or are determined.
B.R.A.H.M.S. GmbH | Date: 2016-07-15
The present invention is in the field of clinical diagnostics. Particularly the present invention relates to the prognosis of adverse events in patients with stable chronic heart failure or being suspected of having stable chronic heart failure by determination of the level of Procalcitonin (PCT).
BRAHMS GmbH | Date: 2016-01-21
The invention relates to a method for risk stratification for acute coronary syndrome (ACS), in particular acute myocardial infarction (AMI) and angina pectoris (AP), wherein provasopressin (proAVP) or fragments and partial peptides thereof, in particular copeptin or neurophysin II, is determined by an in vitro diagnosis.
B.R.A.H.M.S GmbH | Date: 2015-11-12
An in vitro method for the risk stratification of patients with stable arteriosclerosis, especially stable coronary artery disease, is disclosed wherein the concentration of procalcitonin is determined in the circulation of such patients using a highly sensitive PCT assay, and wherein within the range of PCT concentrations in the typical normal range of healthy individuals cutoff values are defined which distinguish groups of individual patients with stable arteriosclerosis in accordance with personal cardiac risk, and patients are allotted to one of said risk groups on the basis of their individual PCT concentrations.
B.R.A.H.M.S GmbH | Date: 2016-06-15
Subject of the present invention is a method of assessing the susceptibility of a subject to acquire cancer and/ or assessing the risk of cancer mortality for a subject, who has not had clinically manifest cancer and/or does not have clinically manifest cancer at the time when applying this method.
The General Hospital Corporation and B.R.A.H.M.S Gmbh | Date: 2015-06-25
Subject of the present invention are assays and in vitro methods for the prediction of the risk of a subject for contracting metabolic syndrome and/or diabetes mellitus and for diagnosing metabolic syndrome, comprising determining the level of arginine vasopres sin pro-hormone or fragments thereof in a sample of a subject.
BRAHMS GmbH | Date: 2016-02-26
The invention relates to a method for diagnosis and/or risk assessment of pancreatic diabetes, in particular of diabetic sequelae, using the marker mid-regional proAdrenomedullin (MR-proADM: SEQ ID No.2) or a partial peptide or fragment thereof. The invention further relates to a diagnostic device and a kit for carrying out the method.